Pharmaceuticals, Biotechnology and Life Sciences
SeaBeLife has received €1.37M ($1.49M) in financing from Bpifrance. This financing, which has been granted in connection with the French government’s ‘Deeptech Plan’, will contribute to research into first-in-class drug candidates for the treatment of acute liver, kidney, heart and brain disease, SeaBeLife said in its press release.
The Phase 2 AMEERA-3 clinical trial evaluating amcenestrant, an investigational optimized oral selective estrogen receptor degrader (SERD), did not meet…
Valneva SE has provided an update on the regulatory review of its inactivated, COVID-19 vaccine candidate, VLA2001, by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
The 16th annual BIO-Europe Spring global life sciences partnering event will be held March 28–31, 2022 in a fully digital…
Exscientia and the University of Oxford Target Discovery Institute (Oxford TDI) have announced the formation of Xcellomics – a program designed to source cellular functional assays from the global academic community to develop novel screens and identify targets and therapeutic candidates for unmet medical needs.
Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in…
Scenic Biotech BV, a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, has closed a Series A financing of ~$31 million (€28 million).
Medexprim has appointed Alexandre Blanchot as Business Development Manager.
Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors.
The New England Journal of Medicine (NEJM) published data showing the Phase III MONALEESA-2 trial for NovartIs’s Kisqali (ribociclib) plus letrozole demonstrated a statistically significant improvement in overall survival.